Yahoo Finance

Dr. Dobranowski further adds, "2024 has been a defining year for HEALWELL, marked by unprecedented and transformational growth. We closed the year with approximately $39 million in revenue, achieving 433% growth and improving profitability. A key driver of this success was our newly acquired subsidiaries, including Intrahealth Solutions, VeroSource Solutions, Bio Pharma Services, and Mutuo Health Solutions. These acquisitions not only strengthened our business from a financials perspective, but also strategically expanded our customer base, artificial intelligence and technology offerings, and brought new market opportunities in both the private and public sectors. Over the past year we also made significant strides in the life sciences sector, ending the year with 30 signed MSAs combined for both Pentavere and Khure Health businesses, which includes agreements with 7 of the top 10 pharmaceutical companies in the world. This is just the beginning of our journey in delivering value to the life sciences sector and we are excited to explore more opportunities with them in 2025."

Anthony Lam, Chief Financial Officer of HEALWELL, commented, "Combined with our recently signed credit agreement, HEALWELL has financing arrangements for over $100 million in place to support the completion of the Orion Health acquisition, which is expected to close on April 1st. We would like to thank our new shareholders and financial banking partners as their support reinforces our ability to execute our strategic vision and unlocks new growth opportunities for the Company. With the acquisition of Orion Health, we will be well positioned to leverage new synergies to enhance operational efficiencies, accelerate growth and drive profitability in the business. Looking ahead, our focus remains on sustaining momentum, increasing Adjusted EBITDA, and creating long-term value for our stakeholders."

Fiscal 2024 Annual Financial Highlights:

Significant financial highlights for the Company's continuing operations during the year ended December 31, 2024 included:

• HEALWELL achieved annual revenue from continuing operations of approximately $39 million during 2024, an increase of 433% compared to revenue of $7.3 million in 2023.

• HEALWELL achieved Gross Profit⁽²⁾ of $17.3 million in 2024, compared to $1.2 million in 2023.

• HEALWELL achieved a Gross Margin⁽²⁾ percentage of 44% during 2024 compared to 17% in 2023.

• During fiscal 2024, HEALWELL reported Adjusted EBITDA⁽¹⁾ loss of $16 million, compared to an Adjusted EBITDA loss of $7.9 million in 2023.

Fourth Quarter 2024 Financial Highlights

Significant financial highlights for the Company's continuing operations during the three months ended December 31, 2024 included:

• HEALWELL achieved quarterly revenue from continuing operations of $15.2 million in Q4-2024, an increase of 692% compared to revenue of $1.9 million generated in Q4-2023. The growth in revenue is primarily attributable acquisitions, including Pentavere Research Group ("Pentavere"), Intrahealth Systems Limited ("Intrahealth"), BioPharma Services Inc. ("BioPharma"), VeroSource Solutions Inc. ("VeroSource") and Mutuo Health Solutions Inc. ("Mutuo"). Mutuo .

• HEALWELL achieved Gross Profit⁽²⁾ of $7.0 million during Q4-2024, an increase of 1,179% compared to $0.54 million in Q4-2023. The increase in Gross Profit is primarily attributed to an increase in revenue from the acquisitions made over the past year.

• HEALWELL achieved a Gross Margin⁽²⁾ percentage of 46% during Q4-2024, compared to 28% in Q4-2023. The improvement in Gross Margin was also primarily due to the contribution of higher gross margin acquisitions of Intrahealth and VeroSource.

• During Q4-2024, HEALWELL reported an Adjusted EBITDA⁽¹⁾ loss of $5.4 million, compared to loss of $1.5 million in Q4-2023.

• As of December 31, 2024, HEALWELL had $9.4 million in cash, compared to $15.2 million as of September 30, 2024.

Fourth Quarter 2024 Business and Operational Highlights

Significant business and operational highlights for the Company during the three months ended December 31, 2024 included:

• Investment in Abstractive Health to Advance Generative AI-Powered Clinical Documentation: On October 22, 2024, HEALWELL announced a USD$250,000 strategic investment and commercialization agreement with Abstractive Health ("Abstractive Health"), a healthcare AI company specializing in providing physicians with an automated, accurate and medically relevant AI assistant that delivers patient summaries using proprietary generative AI technology.

• Acquisition of Mutuo Health Solutions: On November 1, 2024, HEALWELL acquired a 51% controlling interest in Toronto-based Mutuo for a total purchase price of approximately $5.7 million. Mutuo is a Software-as-a-Service (SaaS) platform that utilizes artificial intelligence to automate medical transcription and note generation for healthcare professionals. The company's flagship product, AutoScribe, transcribes clinician-patient conversations into accurate medical notes in real time, integrated seamlessly with Electronic Medical Records (EMR) systems such as PS Suite, Oscar EMR, Cerner, and Epic.

• Expansion of Pharmaceutical Partnerships: On November 5, 2024, HEALWELL announced its subsidiaries executed five new Master Services Agreements (MSAs) with pharmaceutical partners, enhancing commercialization opportunities for its AI-powered patient identification solutions.

• Pentavere Receives Prix Galien USA 2024 Award for Best Digital Health Startup: On November 12, 2024, the Company announced Pentavere received the prestigious Prix Galien USA 2024 Award for Best Digital Health Startup for its contributions in AI and Life Sciences. The Prix Galian Award is among the global health innovation industry's most renowned honors, recognizing outstanding biomedical, medical and technological achievements that improve the human condition.

• VeroSource Solutions Drives Expansion in Canadian Healthcare Sector: On November 27, 2024, HEALWELL's subsidiary, VeroSource Solutions, reported rapid expansion in Canada's public healthcare sector. More than 600,000 New Brunswick residents can now generate a Patient Summary via the MyHealthNB platform, powered by VeroSource technology.

• HEALWELL to Acquire Orion Health, Creating a Global Leader in AI-Driven Healthcare: On December 16, 2024, HEAWELL announced that it entered into an agreement to acquire 100% of the shares of Auckland, New Zealand based Orion Health, a subscription license and services revenue business serving marquee public sector clients globally with data interoperability and healthcare navigation products and services. The aggregate purchase price of the transaction is $175 million NZD plus a performance based earnout of up to a further $25 million NZD. On closing, HEALWELL will satisfy the purchase price of $144 million CAD with$86 million CAD in cash and $57.4 million CAD in HEALWELL Class A Subordinate Voting Shares. The acquisition of Orion Health will represent a transformative milestone in HEALWELL's journey to become a global leader in healthcare technology and artificial intelligence. The transaction is expected to close on April 1, 2025 and remains subject to a limited number of conditions precedent.

• HEALWELL Upsizes Bought Deal Offering to $55 Million: On December 16, 2024 and December 17, 2024, the Company announced that it had entered into (and subsequently amended) a letter agreement to complete a $55.0 million subscription receipt financing, on a bought-deal basis, to support the acquisition of Orion Health (the "Bought-Deal Acquisition Financing"), with Eight Capital and Scotia Capital Inc. acting as joint-bookrunners on behalf of a syndicate of underwriters.

Events Subsequent to December 31, 2024

Significant business and operational highlights for the Company subsequent to December 31, 2024 included:

• Shareholder Approval for Orion Health Acquisition: On January 15, 2025, HEALWELL obtained written shareholder approval for its pending acquisition of Orion Health and related financing. This approval represents a key step in finalizing the acquisition and integrating Orion Health into HEALWELL's growing AI-driven healthcare ecosystem.

• $25.5M Equity Tranche Completion: On January 21, 2025, HEALWELL announced the closing of the first tranche of its Bought Deal Acquisition Financing, raising aggregate gross proceeds of approximately $25.5 million.

• $30M Convertible Debt Tranche Closure: On January 28, 2025, HEALWELL announced the closing of the second tranche of its Bought Deal Acquisition Financing, raising aggregate gross proceeds of $27.3 million, after considering the OID (Original Issue Discount) on the underlying debentures.

• Strategic Cost Optimization Initiative: On February 3, 2025, HEALWELL provided a corporate update highlighting a cost optimization initiative aimed at streamlining operations and maximizing M&A efficiencies. The Company expects to achieve at least $3.0 million in annual cost savings, reinforcing its commitment to operational excellence.

• Khure Health's Expansion in AI-Powered Disease Detection: On February 24, 2025, HEALWELL's Khure Health reported a significant acceleration in user adoption and partnerships in its AI-powered co-pilots for disease detection. In Q4 2024 alone, Khure Health assisted physicians in identifying over 43,000 high-risk patients, further strengthening its impact on preventive care and physician support.

• $50M Credit Agreement Led by Scotiabank and RBC to Support Orion Acquisition: On February 26, 2025, HEALWELL announced the signing of a $50 million credit agreement, led by Scotiabank and RBC, to support its acquisition of Orion Health. The financing includes a $20 million term loan and a $30 million revolving credit facility, with an additional uncommitted accordion feature of up to $25 million. Combined with recent capital raises, HEALWELL has secured over $100 million in funding for the transaction. The Company has initiated the pre-closing reorganization process with a target closing date of April 1, 2025, marking a significant step in expanding its global healthcare intelligence platform.

Webcast and Conference Call Details:

HEALWELL will be holding a conference call and simultaneous webcast to discuss its financial results on Wednesday, March 26, 2025 at 1:00 pm ET (10:00 am PT). The call will be hosted by Dr. Alexander Dobranowski, Chief Executive Officer, and Anthony Lam, Chief Financial Officer. Please dial-in 10 minutes prior to the start of the call.

Date: Wednesday, March 26, 2025
Time: 1:00 PM ET / 10:00 AM PT
Webcast link: https://www.gowebcasting.com/13983
Toll-Free North America: 1-833-752-3509
International Toll: 1-647-846-7993

HEALWELL AI INC. (formerly known as MCI ONEHEALTH TECHNOLOGIES INC.)
Consolidated Statement of Financial Position
(In thousands of Canadian dollars, except per share amounts)

HEALWELL AI INC. (formerly known as MCI ONEHEALTH TECHNOLOGIES INC.)
Consolidated Statement of Profit (Loss) and Comprehensive Income (Loss)
(In thousands of Canadian dollars, except per share amounts)
For the years ended 31 December 2024 and 2023

HEALWELL AI INC. (formerly known as MCI ONEHEALTH TECHNOLOGIES INC.)
Consolidated Statement of Cash Flows
(In thousands of Canadian dollars, except per share amounts)
For the years ended 31 December 2024

Selected Financial Information
(in thousands of dollars, except percentages and per share amounts)

(1) Adjusted EBITDA and Adjusted EBITDA Margin are non-IFRS measures. Please see "Non-IFRS Measures" above for an explanation of the composition of these measures and their usefulness, and "Reconciliation of Non-IFRS Measures" below for a reconciliation of these measures to the IFRS measures found in the Financial Statements.
(2) Certain Financial Statement Line Items on the 2023 Profit and Loss Statement have been re-classified to conform to the methodology used to prepare the 2024 Profit and Loss statement.

Selected Statement of Financial Position Data

Non-IFRS Financial Measures

The terms Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Gross Profit and Adjusted Gross Margin used in this document do not have any standardized meaning under IFRS, may not be comparable to similar financial measures disclosed by other companies and should not be considered a substitute for, or superior to, IFRS financial measures. Readers are advised to review the section entitled "Non-IFRS Financial Measures" in the Company's management discussion and analysis for the quarter and year ended December 31, 2024, available on the Company's SEDAR+ page at www.sedarplus.ca, for a detailed explanation of the composition of these measures and their uses.

The following table reconciles Adjusted EBITDA and Adjusted EBITDA Margin to net income (loss) for the three-months and fiscal year ended December 31, 2024 and December 31, 2023: